Compare Morgan Stanley (MS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Novavax Inc — how do they compare? Morgan Stanley trades at $187.81 (market cap $297.95B), while Novavax Inc trades at $11 (market cap $1.85B). The key difference: Morgan Stanley is far larger — about 161.1× Novavax Inc's market cap, and Morgan Stanley pays a 2.42% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 93 Days and Novavax Inc for 59 Days on average.
| MS | NVAX | |
|---|---|---|
Market Cap | $297.95B | $1.85B |
Volume | 5,030,247 | 8,362,562 |
Sector | Financials | Health |
52-Week High | $228.42 | $12.56 |
52-Week Low | $151.86 | $6.22 |
Typical Hold Time | 93 Days | 59 Days |
Enterprise Value | $663.67B | $1.43B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $187.41, down 1.86% on the day, with a bearish technical signal but strong fundamentals including a P/E of 15.32 and net income margin of 27.59%. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $50.2B in 2022 to $66.0B in 2025, and the company highlights growth opportunities in wealth management and AI financing.
The outlook is supported by a bullish analyst consensus with a $229.25 price target, though risks include volatile cash flows and rising debt-to-asset ratios. Near-term price action is testing support near $184, with investor sentiment mixed amid fading capital markets momentum but positive long-term growth narratives.
Novavax (NVAX) trades at $11.01, down 2.74% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported strong revenue of $1.12B in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Recent news highlights the company's pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in major markets.
Investment outlook remains speculative with analyst consensus heavily favoring Buy ratings (73.92%) but fundamental risks persist including negative cash flow trends and high debt levels. The stock offers potential upside from partnership expansions but faces significant execution and competitive risks in the biopharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
